Business Description
Sun Pharmaceuticals Industries Ltd
ISIN : INE044A01036
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8.18 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.14 | |||||
Interest Coverage | 39.38 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 14.9 | |||||
Beneish M-Score | -2.06 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.2 | |||||
3-Year EBITDA Growth Rate | 18.1 | |||||
3-Year EPS without NRI Growth Rate | 30.3 | |||||
3-Year FCF Growth Rate | -16.9 | |||||
3-Year Book Growth Rate | 7.3 | |||||
Future 3-5Y Total Revenue Growth Rate | 10.5 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47.46 | |||||
9-Day RSI | 41.19 | |||||
14-Day RSI | 41.69 | |||||
6-1 Month Momentum % | 43.61 | |||||
12-1 Month Momentum % | 65.44 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.62 | |||||
Quick Ratio | 1.96 | |||||
Cash Ratio | 1.05 | |||||
Days Inventory | 350.53 | |||||
Days Sales Outstanding | 91.09 | |||||
Days Payable | 190.48 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.84 | |||||
Dividend Payout Ratio | 0.29 | |||||
3-Year Dividend Growth Rate | 22.2 | |||||
Forward Dividend Yield % | 0.84 | |||||
5-Year Yield-on-Cost % | 3.58 | |||||
Shareholder Yield % | 0.39 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 77.43 | |||||
Operating Margin % | 21.74 | |||||
Net Margin % | 19.08 | |||||
FCF Margin % | 6.16 | |||||
ROE % | 15.82 | |||||
ROA % | 11.39 | |||||
ROIC % | 15.25 | |||||
ROC (Joel Greenblatt) % | 49.14 | |||||
ROCE % | 17.65 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 40.49 | |||||
PE Ratio without NRI | 38.43 | |||||
Shiller PE Ratio | 53.97 | |||||
Price-to-Owner-Earnings | 86.86 | |||||
PEG Ratio | 3.23 | |||||
PS Ratio | 7.72 | |||||
PB Ratio | 6.03 | |||||
Price-to-Tangible-Book | 8.68 | |||||
Price-to-Free-Cash-Flow | 125.46 | |||||
Price-to-Operating-Cash-Flow | 72.71 | |||||
EV-to-EBIT | 32.58 | |||||
EV-to-Forward-EBIT | 24.18 | |||||
EV-to-EBITDA | 26.29 | |||||
EV-to-Forward-EBITDA | 19.77 | |||||
EV-to-Revenue | 7.52 | |||||
EV-to-Forward-Revenue | 5.64 | |||||
EV-to-FCF | 122.33 | |||||
Price-to-Projected-FCF | 4.41 | |||||
Price-to-DCF (Earnings Based) | 4.19 | |||||
Price-to-DCF (FCF Based) | 13.67 | |||||
Price-to-Median-PS-Value | 1.45 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.44 | |||||
Price-to-Graham-Number | 3.96 | |||||
Price-to-Net-Current-Asset-Value | 18.48 | |||||
Earnings Yield (Greenblatt) % | 3.07 | |||||
FCF Yield % | 0.79 | |||||
Forward Rate of Return (Yacktman) % | 12.85 |